LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 9 of total 9

Search options

  1. Article ; Online: Clinical presentation of hereditary angioedema.

    Azmy, Veronica / Brooks, Joel P / Hsu, F Ida

    Allergy and asthma proceedings

    2020  Volume 41, Issue Suppl 1, Page(s) S18–S21

    Abstract: Hereditary angioedema (HAE) is a rare, autosomal dominant disease caused by a deficiency in the C1-inhibitor protein. It is characterized by recurrent episodes of nonpruritic, nonpitting, subcutaneous or submucosal edema that typically involves the ... ...

    Abstract Hereditary angioedema (HAE) is a rare, autosomal dominant disease caused by a deficiency in the C1-inhibitor protein. It is characterized by recurrent episodes of nonpruritic, nonpitting, subcutaneous or submucosal edema that typically involves the extremities or the gastrointestinal tract. However, the genitourinary tract, face, oropharynx, and/or larynx may be affected as well. Symptoms often begin in childhood, worsen at puberty, and persist throughout life, with unpredictable severity. Patients who are untreated may have frequent attacks, with intervals that can range from every few days to rare episodes. Minor trauma and stress are frequent precipitants of swelling episodes, but many attacks occur without clear triggers. HAE attacks may be preceded by a prodrome and/or be accompanied by erythema marginatum. The swelling typically worsens over the first 24 hours, before gradually subsiding over the subsequent 48 to 72 hours. Although oropharyngeal swelling is less frequent, more than half of patients have had at least one episode of laryngeal angioedema during their lifetime. Attacks may start in one location and spread to another before resolving. HAE attacks that involve the abdomen or oropharynx have been associated with significant morbidity and mortality. Abdominal attacks can cause severe abdominal pain, nausea, and vomiting. Bowel sounds are often diminished or silent, and guarding and rebound tenderness may be present on physical examination. These findings may lead to unnecessary abdominal imaging and procedures. Fluid shifts into the interstitial space or peritoneal cavity can cause clinically significant hypotension. Laryngeal edema poses the greatest risk for patients with HAE. Although prompt diagnosis and treatment improves outcomes, the variable presentation of HAE can make it difficult to diagnose.
    MeSH term(s) Abdomen/pathology ; Angioedemas, Hereditary/pathology ; Angioedemas, Hereditary/physiopathology ; Animals ; Diagnostic Errors ; Edema ; Extremities/pathology ; Humans ; Hypotension
    Language English
    Publishing date 2020-10-28
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't ; Review
    ZDB-ID 1312445-6
    ISSN 1539-6304 ; 1088-5412
    ISSN (online) 1539-6304
    ISSN 1088-5412
    DOI 10.2500/aap.2020.41.200065
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Experience with Intravenous Plasma-Derived C1-Inhibitor in Pregnant Women with Hereditary Angioedema: A Systematic Literature Review.

    Brooks, Joel P / Radojicic, Cristine / Riedl, Marc A / Newcomer, Scott D / Banerji, Aleena / Hsu, F Ida

    The journal of allergy and clinical immunology. In practice

    2020  Volume 8, Issue 6, Page(s) 1875–1880.e3

    Abstract: Consensus guidelines recommend plasma-derived C1 inhibitor (C1-INH) as first-line treatment in pregnant women with hereditary angioedema (HAE). We conducted a systematic review of the literature that describes experience with plasma-derived C1-INH during ...

    Abstract Consensus guidelines recommend plasma-derived C1 inhibitor (C1-INH) as first-line treatment in pregnant women with hereditary angioedema (HAE). We conducted a systematic review of the literature that describes experience with plasma-derived C1-INH during pregnancy. A literature search of PubMed was conducted in November 2018 using variants of "hereditary angioedema" and "pregnancy." English language articles that presented original data about the use of plasma-derived C1-INH during pregnancy were selected for data extraction. The search returned 253 unique records, of which 40 described the use of C1-INH during pregnancy (91 patients, 136 pregnancies). When the number of doses was reported, a total of 1562 doses were administered ranging from 500 to 3000 IU. Infusions were administered during all 3 trimesters and were most commonly administered during the third trimester. Overall, 1,490,500 IU of plasma-derived C1-INH were administered during pregnancy. Of the 128 fetuses for which outcomes were reported, 3 (2%) resulted in spontaneous abortion, 1 (1%) was stillborn, and 1 (1%) was a vanishing twin. Use of plasma-derived C1-INH in women with HAE during pregnancy has been widely reported in the scientific literature and has a favorable safety profile, supporting treatment guideline recommendations.
    MeSH term(s) Administration, Intravenous ; Angioedemas, Hereditary/drug therapy ; Complement C1 Inhibitor Protein/therapeutic use ; Female ; Humans ; Plasma ; Pregnancy ; Pregnancy Trimesters ; Pregnant Women
    Chemical Substances Complement C1 Inhibitor Protein
    Language English
    Publishing date 2020-04-03
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't ; Systematic Review
    ZDB-ID 2843237-X
    ISSN 2213-2201 ; 2213-2198
    ISSN (online) 2213-2201
    ISSN 2213-2198
    DOI 10.1016/j.jaip.2020.03.009
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article: Clinical profile and treatment outcomes in patients with hereditary angioedema with normal C1 esterase inhibitor.

    Jones, Douglas H / Bansal, Priya / Bernstein, Jonathan A / Fatteh, Shahnaz / Harper, Joseph / Hsu, F Ida / O'Connor, Maeve / Park, Nami / Suez, Daniel

    The World Allergy Organization journal

    2022  Volume 15, Issue 1, Page(s) 100621

    Abstract: Background: Hereditary angioedema (HAE) is often caused by low serum levels or functional deficiency in C1 inhibitor (C1-INH); however, in some cases, C1-INH serum level and function are measured as normal (HAE-nl-C1INH). Management of HAE-nl-C1INH is ... ...

    Abstract Background: Hereditary angioedema (HAE) is often caused by low serum levels or functional deficiency in C1 inhibitor (C1-INH); however, in some cases, C1-INH serum level and function are measured as normal (HAE-nl-C1INH). Management of HAE-nl-C1INH is similar to management of HAE with C1-INH deficiency, including on-demand therapy for angioedema attacks and, potentially, prophylaxis. Recombinant human C1 esterase inhibitor (rhC1-INH) is indicated for treatment of acute HAE attacks. This study assessed the clinical profile and treatment outcomes in an HAE-nl-C1INH population with a history of rhC1-INH treatment.
    Methods: Medical records containing patient-reported outcomes from ten US treatment centers were analyzed retrospectively for medical history, angioedema attack characteristics, attack treatments, and clinical outcomes.
    Results: Twenty-three patients were included, with wide US geographic representation. Most patients (87.0%) were female; median age was 36.0 years (range, 19-67 years). Of 20 patients with available data, 4 had their first angioedema attack during childhood (aged <12 years), 3 during adolescence (aged 12-17 years), and 13 during adulthood (aged 18-29 years, n = 7; aged ≥30 years, n = 6). Median age at HAE-nl-C1INH diagnosis was 31.5 years (range, 9-59 years). Previous failed treatments included high-dose antihistamines (n = 20) and corticosteroids (n = 20). Use of US Food and Drug Administration (FDA)-approved HAE therapy positively impacted patient-reported assessments of angioedema attacks. Most patients were taking rhC1-INH or lanadelumab as prophylaxis and icatibant or rhC1-INH for acute management. Most patients reported improved disease control with these therapies, including reductions in angioedema attack frequency and severity. Although most patients were receiving prophylactic therapy, availability of treatment for breakthrough attacks was important.
    Conclusion: Findings from this retrospective study support use of FDA-approved HAE medications for prophylaxis and acute treatment of HAE attacks in patients with HAE-nl-C1INH. Individualized HAE treatment regimens were needed to optimize therapeutic outcomes.
    Language English
    Publishing date 2022-01-27
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2581968-9
    ISSN 1939-4551
    ISSN 1939-4551
    DOI 10.1016/j.waojou.2021.100621
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Etoposide phosphate for pediatric orthopedic malignancies after intravenous etoposide hypersensitivity.

    Brooks, Joel P / Azmy, Veronica / Thompson, Alison / Luon, Darren / Prozora, Stephanie D / Price, Christina / Hsu, F Ida

    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners

    2019  Volume 26, Issue 1, Page(s) 228–231

    Abstract: Background: Hypersensitivity reactions to etoposide have been reported and patients have been safely transitioned to etoposide phosphate for continued therapy. However, the safety and efficacy of substituting etoposide phosphate for etoposide has not ... ...

    Abstract Background: Hypersensitivity reactions to etoposide have been reported and patients have been safely transitioned to etoposide phosphate for continued therapy. However, the safety and efficacy of substituting etoposide phosphate for etoposide has not been well established in pediatric orthopedic malignancies. The aim of this study is to determine whether etoposide phosphate can be substituted for etoposide in pediatric orthopedic malignancies.
    Methods: A chart review of pediatric patients who developed hypersensitivity reactions to etoposide while being treated for orthopedic malignancies was performed at a large academic medical center. Three patients were identified, two with Ewing sarcoma and one with an osteosarcoma. All three patients experienced hypersensitivity reactions to their first doses of etoposide and were switched to etoposide phosphate for further therapy.
    Results: After premedication, all three patients tolerated full doses of etoposide phosphate without a graded dose challenge or desensitization. Two of the patients were premedicated with diphenhydramine alone, while the third received diphenhydramine and dexamethasone.
    Conclusions: Etoposide phosphate is a potentially safe alternative for pediatric patients with orthopedic malignancies who experience etoposide hypersensitivity. However, caution is needed as there are cases of etoposide phosphate hypersensitivity.
    MeSH term(s) Adolescent ; Bone Neoplasms/drug therapy ; Drug Hypersensitivity/etiology ; Etoposide/adverse effects ; Etoposide/analogs & derivatives ; Etoposide/therapeutic use ; Humans ; Male ; Organophosphorus Compounds/therapeutic use ; Osteosarcoma/drug therapy ; Sarcoma, Ewing/drug therapy
    Chemical Substances Organophosphorus Compounds ; etoposide phosphate (528XYJ8L1N) ; Etoposide (6PLQ3CP4P3)
    Language English
    Publishing date 2019-03-18
    Publishing country England
    Document type Case Reports ; Journal Article
    ZDB-ID 1330764-2
    ISSN 1477-092X ; 1078-1552
    ISSN (online) 1477-092X
    ISSN 1078-1552
    DOI 10.1177/1078155219836478
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Recombinant human C1 esterase inhibitor as short-term prophylaxis in patients with hereditary angioedema.

    Valerieva, Anna / Staevska, Maria / Jesenak, Milos / Hrubiskova, Katarina / Sobotkova, Marta / Zachova, Radana / Hakl, Roman / Andrejevic, Sladjana / Suiter, Tobias / Grivcheva-Panovska, Vesna / Karadza-Lapic, Ljerka / Soteres, Daniel / Shapiro, Ralph / Rumbyrt, Jeffrey / Tachdjian, Raffi / Mehta, Vinay / Hsu, F Ida / Zanichelli, Andrea

    The journal of allergy and clinical immunology. In practice

    2019  Volume 8, Issue 2, Page(s) 799–802

    MeSH term(s) Angioedemas, Hereditary/drug therapy ; Angioedemas, Hereditary/prevention & control ; Complement C1 Inactivator Proteins ; Complement C1 Inhibitor Protein/therapeutic use ; Esterases ; Humans ; Recombinant Proteins
    Chemical Substances Complement C1 Inactivator Proteins ; Complement C1 Inhibitor Protein ; Recombinant Proteins ; Esterases (EC 3.1.-)
    Language English
    Publishing date 2019-08-19
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2843237-X
    ISSN 2213-2201 ; 2213-2198
    ISSN (online) 2213-2201
    ISSN 2213-2198
    DOI 10.1016/j.jaip.2019.08.011
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Hypersensitivity reactions to mAbs: 105 desensitizations in 23 patients, from evaluation to treatment.

    Brennan, Patrick J / Rodriguez Bouza, Tito / Hsu, F Ida / Sloane, David E / Castells, Mariana C

    The Journal of allergy and clinical immunology

    2009  Volume 124, Issue 6, Page(s) 1259–1266

    Abstract: Background: Rapid desensitization, a procedure for graded drug administration, allows for the safe readministration of a medication after certain types of hypersensitivity reactions (HSRs) and is indicated in cases in which there are no reasonable ... ...

    Abstract Background: Rapid desensitization, a procedure for graded drug administration, allows for the safe readministration of a medication after certain types of hypersensitivity reactions (HSRs) and is indicated in cases in which there are no reasonable therapeutic alternatives. The use of rapid desensitization for HSRs to mAbs has not been validated.
    Objective: We sought to describe our experience with rapid desensitization to mAbs, including rituximab, infliximab, and trastuzumab.
    Methods: One hundred five rapid desensitizations were performed in 23 patients with a standardized 12-step, 6-hour protocol. Our approach to patient evaluation before desensitization is described. The severity, characteristics, and timing of both initial HSRs and HSRs during desensitization were determined by means of retrospective review of medical records. After a reaction during desensitization, patient-specific protocol modifications were made before each subsequent desensitization.
    Results: 104 of 105 desensitizations undertaken were successfully completed. We observed HSRs during 29% of desensitizations, including 27 mild reactions, 1 moderate reaction, and 2 severe reactions. Overall, reactions during desensitization were markedly less severe than initial HSRs, but reactions did recur in a minority of successive desensitizations.
    Conclusions: Rapid desensitization is a promising method for the delivery of monoclonal therapeutics after an HSR, but the possibility of a reaction remains with each desensitization.
    MeSH term(s) Adult ; Aged ; Antibodies, Monoclonal/administration & dosage ; Antibodies, Monoclonal/adverse effects ; Antibodies, Monoclonal, Humanized ; Antibodies, Monoclonal, Murine-Derived ; Desensitization, Immunologic/methods ; Drug Hypersensitivity/immunology ; Drug Hypersensitivity/therapy ; Female ; Humans ; Infliximab ; Male ; Middle Aged ; Retrospective Studies ; Rituximab ; Skin Tests ; Trastuzumab
    Chemical Substances Antibodies, Monoclonal ; Antibodies, Monoclonal, Humanized ; Antibodies, Monoclonal, Murine-Derived ; Rituximab (4F4X42SYQ6) ; Infliximab (B72HH48FLU) ; Trastuzumab (P188ANX8CK)
    Language English
    Publishing date 2009-12
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 121011-7
    ISSN 1097-6825 ; 1085-8725 ; 0091-6749
    ISSN (online) 1097-6825 ; 1085-8725
    ISSN 0091-6749
    DOI 10.1016/j.jaci.2009.09.009
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Patients with common variable immunodeficiency with autoimmune cytopenias exhibit hyperplastic yet inefficient germinal center responses.

    Romberg, Neil / Le Coz, Carole / Glauzy, Salomé / Schickel, Jean-Nicolas / Trofa, Melissa / Nolan, Brian E / Paessler, Michele / Xu, Mina L / Lambert, Michele P / Lakhani, Saquib A / Khokha, Mustafa K / Jyonouchi, Soma / Heimall, Jennifer / Takach, Patricia / Maglione, Paul J / Catanzaro, Jason / Hsu, F Ida / Sullivan, Kathleen E / Cunningham-Rundles, Charlotte /
    Meffre, Eric

    The Journal of allergy and clinical immunology

    2018  Volume 143, Issue 1, Page(s) 258–265

    Abstract: Background: The lack of pathogen-protective, isotype-switched antibodies in patients with common variable immunodeficiency (CVID) suggests germinal center (GC) hypoplasia, yet a subset of patients with CVID is paradoxically affected by autoantibody- ... ...

    Abstract Background: The lack of pathogen-protective, isotype-switched antibodies in patients with common variable immunodeficiency (CVID) suggests germinal center (GC) hypoplasia, yet a subset of patients with CVID is paradoxically affected by autoantibody-mediated autoimmune cytopenias (AICs) and lymphadenopathy.
    Objective: We sought to compare the physical characteristics and immunologic output of GC responses in patients with CVID with AIC (CVID+AIC) and without AIC (CVID-AIC).
    Methods: We analyzed GC size and shape in excisional lymph node biopsy specimens from 14 patients with CVID+AIC and 4 patients with CVID-AIC. Using paired peripheral blood samples, we determined how AICs specifically affected B-and T-cell compartments and antibody responses in patients with CVID.
    Results: We found that patients with CVID+AIC displayed irregularly shaped hyperplastic GCs, whereas GCs were scarce and small in patients with CVID-AIC. GC hyperplasia was also evidenced by an increase in numbers of circulating follicular helper T cells, which correlated with decreased regulatory T-cell frequencies and function. In addition, patients with CVID+AIC had serum endotoxemia associated with a dearth of isotype-switched memory B cells that displayed significantly lower somatic hypermutation frequencies than their counterparts with CVID-AIC. Moreover, IgG
    Conclusions: Patients with CVID+AIC do not contain mucosal microbiota and exhibit hyperplastic yet inefficient GC responses that favor the production of untolerized IgG
    MeSH term(s) Adolescent ; Adult ; Aged ; Autoantibodies/immunology ; B-Lymphocytes/immunology ; B-Lymphocytes/pathology ; Biopsy ; Child ; Common Variable Immunodeficiency/immunology ; Common Variable Immunodeficiency/pathology ; Female ; Germinal Center/immunology ; Germinal Center/pathology ; Humans ; Hyperplasia ; Immunoglobulin G/immunology ; Male ; Middle Aged ; T-Lymphocytes/immunology ; T-Lymphocytes/pathology
    Chemical Substances Autoantibodies ; Immunoglobulin G
    Language English
    Publishing date 2018-06-20
    Publishing country United States
    Document type Clinical Trial ; Journal Article ; Multicenter Study ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
    ZDB-ID 121011-7
    ISSN 1097-6825 ; 1085-8725 ; 0091-6749
    ISSN (online) 1097-6825 ; 1085-8725
    ISSN 0091-6749
    DOI 10.1016/j.jaci.2018.06.012
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article: Cysteinyl leukotrienes regulate Th2 cell-dependent pulmonary inflammation.

    Kim, Daniel C / Hsu, F Ida / Barrett, Nora A / Friend, Daniel S / Grenningloh, Roland / Ho, I-Cheng / Al-Garawi, Amal / Lora, Jose M / Lam, Bing K / Austen, K Frank / Kanaoka, Yoshihide

    Journal of immunology (Baltimore, Md. : 1950)

    2006  Volume 176, Issue 7, Page(s) 4440–4448

    Abstract: The Th2 cell-dependent inflammatory response is a central component of asthma, and the ways in which it is regulated is a critical question. The cysteinyl leukotrienes (cys-LTs) are 5-lipoxygenase pathway products implicated in asthma, in particular, by ... ...

    Abstract The Th2 cell-dependent inflammatory response is a central component of asthma, and the ways in which it is regulated is a critical question. The cysteinyl leukotrienes (cys-LTs) are 5-lipoxygenase pathway products implicated in asthma, in particular, by their function as smooth muscle constrictors of airways and microvasculature. To elucidate additional roles for cys-LTs in the pathobiology of pulmonary inflammation, we used an OVA sensitization and challenge protocol with mice lacking leukotriene C(4) synthase (LTC(4)S), the terminal enzyme for cys-LT generation. Ag-induced pulmonary inflammation, characterized by eosinophil infiltration, goblet cell hyperplasia with mucus hypersecretion, and accumulation and activation of intraepithelial mast cells was markedly reduced in LTC(4)S(null) mice. Furthermore, Ag-specific IgE and IgG1 in serum, Th2 cell cytokine mRNA expression in the lung, and airway hyperresponsiveness to methacholine were significantly reduced in LTC(4)S(null) mice compared with wild-type controls. Finally, the number of parabronchial lymph node cells from sensitized LTC(4)S(null) mice and their capacity to generate Th2 cell cytokines ex vivo after restimulation with Ag were also significantly reduced. In contrast, delayed-type cutaneous hypersensitivity, a prototypic Th1 cell-dependent response, was intact in LTC(4)S(null) mice. These findings provide direct evidence of a role for cys-LTs in regulating the initiation and/or amplification of Th2 cell-dependent pulmonary inflammation.
    MeSH term(s) Animals ; Antigen Presentation ; B-Lymphocytes/immunology ; B-Lymphocytes/metabolism ; Cell Differentiation ; Cysteine/metabolism ; Cytokines/biosynthesis ; Gene Expression Regulation/drug effects ; Gene Expression Regulation/genetics ; Immunoglobulins/immunology ; Leukotrienes/metabolism ; Lymph Nodes/drug effects ; Lymph Nodes/metabolism ; Mice ; Mice, Inbred BALB C ; Mice, Knockout ; Ovalbumin/pharmacology ; Pneumonia/chemically induced ; Pneumonia/immunology ; Pneumonia/metabolism ; Pneumonia/pathology ; RNA, Messenger/genetics ; Th2 Cells/cytology ; Th2 Cells/drug effects ; Th2 Cells/immunology ; Th2 Cells/metabolism
    Chemical Substances Cytokines ; Immunoglobulins ; Leukotrienes ; RNA, Messenger ; cysteinyl-leukotriene ; Ovalbumin (9006-59-1) ; Cysteine (K848JZ4886)
    Language English
    Publishing date 2006-01-11
    Publishing country United States
    Document type Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
    ZDB-ID 3056-9
    ISSN 1550-6606 ; 0022-1767 ; 1048-3233 ; 1047-7381
    ISSN (online) 1550-6606
    ISSN 0022-1767 ; 1048-3233 ; 1047-7381
    DOI 10.4049/jimmunol.176.7.4440
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases.

    Castells, Mariana C / Tennant, Nichole M / Sloane, David E / Hsu, F Ida / Barrett, Nora A / Hong, David I / Laidlaw, Tanya M / Legere, Henry J / Nallamshetty, Samridhi N / Palis, Ross I / Rao, Jayanti J / Berlin, Suzanne T / Campos, Susana M / Matulonis, Ursula A

    The Journal of allergy and clinical immunology

    2008  Volume 122, Issue 3, Page(s) 574–580

    Abstract: Background: Hypersensitivity reactions (HSRs) to chemotherapeutic drugs, including mAbs, often require that the provoking medication be discontinued, thus raising a dilemma for the caregiver: further use could precipitate a severe, even fatal, allergic ... ...

    Abstract Background: Hypersensitivity reactions (HSRs) to chemotherapeutic drugs, including mAbs, often require that the provoking medication be discontinued, thus raising a dilemma for the caregiver: further use could precipitate a severe, even fatal, allergic reaction on re-exposure, but alternative drugs might be poorly tolerated or much less effective compared with the preferred agent.
    Objective: We have developed a standardized rapid desensitization protocol for achieving temporary tolerization to drug allergens. In this study we evaluate the safety and efficacy of this protocol.
    Methods: Ninety-eight patients who had HSRs in response to treatment with carboplatin, cisplatin, oxaliplatin, paclitaxel, liposomal doxorubicin, doxorubicin, or rituximab received rapid desensitization to these agents. A standardized 12-step protocol was used, with treatment given intravenously or intraperitoneally. Initial desensitizations occurred in the medical intensive care unit, whereas most subsequent infusions took place in an outpatient setting. Safety and efficacy of the protocol were assessed by review of treatment records.
    Results: Of the 413 desensitizations performed, 94% induced mild or no reactions. No life-threatening HSRs or deaths occurred during the procedure, and all patients received their full target dose. Most reactions occurred during the first desensitization. Reactions were most commonly reported at the last step of the protocol. Desensitizations through the intravenous and intraperitoneal routes were equally effective.
    Conclusions: Our standardized 12-step protocol for rapid drug desensitization is safe and effective and has been adopted as the standard of care at our institutions in treating patients with HSRs to chemotherapeutic drugs, including mAbs.
    MeSH term(s) Adult ; Aged ; Antineoplastic Agents/administration & dosage ; Antineoplastic Agents/adverse effects ; Clinical Protocols ; Desensitization, Immunologic/adverse effects ; Desensitization, Immunologic/methods ; Drug Hypersensitivity/immunology ; Drug Hypersensitivity/therapy ; Female ; Humans ; Male ; Middle Aged ; Skin Tests ; Treatment Outcome
    Chemical Substances Antineoplastic Agents
    Language English
    Publishing date 2008-09
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 121011-7
    ISSN 1097-6825 ; 1085-8725 ; 0091-6749
    ISSN (online) 1097-6825 ; 1085-8725
    ISSN 0091-6749
    DOI 10.1016/j.jaci.2008.02.044
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top